Literature DB >> 17552924

Oncoproteomics: current trends and future perspectives.

William C S Cho1, Christopher H K Cheng.   

Abstract

Oncoproteomics is the application of proteomics technologies in oncology. Functional proteomics is a promising technique for the rational identification of biomarkers and novel therapeutic targets for cancers. Recent progress in proteomics has opened new avenues for tumor-associated biomarker discovery. With the advent of new and improved proteomics technologies, such as the development of quantitative proteomic methods, high-resolution, -speed and -sensitivity mass spectrometry and protein arrays, as well as advanced bioinformatics for data handling and interpretation, it is now possible to discover biomarkers that can reliably and accurately predict outcomes during cancer management and treatment. However, there are several difficulties in the study of proteins/peptides that are not inherent in the study of nucleic acids. New challenges arise in large-scale proteomic profiling when dealing with complex biological mixtures. Nevertheless, oncoproteomics offers great promise for unveiling the complex molecular events of tumorigenesis, as well as those that control clinically important tumor behaviors, such as metastasis, invasion and resistance to therapy. In this review, the development and advancement of oncoproteomics technologies for cancer research in recent years are expounded.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552924     DOI: 10.1586/14789450.4.3.401

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  30 in total

1.  New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Renyong Guo; Chunqin Pan; Jianmin Shen; Chibo Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-21       Impact factor: 4.553

2.  Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Authors:  Fengwei Tan; Ying Jiang; Nan Sun; Zhaoli Chen; Yongzhuang Lv; Kang Shao; Ning Li; Bin Qiu; Yibo Gao; Baozhong Li; Xiaogang Tan; Fang Zhou; Zhen Wang; Dapeng Ding; Jiwen Wang; Jian Sun; Jie Hang; Susheng Shi; Xiaoli Feng; Fuchu He; Jie He
Journal:  Mol Cell Proteomics       Date:  2011-11-07       Impact factor: 5.911

3.  Microscale functional cytomics for studying hematologic cancers.

Authors:  Edmond W K Young; Chorom Pak; Brad S Kahl; David T Yang; Natalie S Callander; Shigeki Miyamoto; David J Beebe
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

Review 4.  Targeting stem cells-clinical implications for cancer therapy.

Authors:  Lan Chun Tu; Greg Foltz; Edward Lin; Leroy Hood; Qiang Tian
Journal:  Curr Stem Cell Res Ther       Date:  2009-05       Impact factor: 3.828

5.  Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis.

Authors:  W C S Cho; T T Yip; W W Cheng; J S K Au
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

6.  A novel preprocessing method using Hilbert Huang Transform for MALDI-TOF and SELDI-TOF mass spectrometry data.

Authors:  Li-Ching Wu; Hsin-Hao Chen; Jorng-Tzong Horng; Chen Lin; Norden E Huang; Yu-Che Cheng; Kuang-Fu Cheng
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

7.  Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.

Authors:  Yoshio Araki; Kazuhiro Yoshikawa; Sho Okamoto; Masaki Sumitomo; Mikio Maruwaka; Toshihiko Wakabayashi
Journal:  BMC Neurol       Date:  2010-11-08       Impact factor: 2.474

Review 8.  Innovations, challenges and future prospects of oncoproteomics.

Authors:  Kewal K Jain
Journal:  Mol Oncol       Date:  2008-05-28       Impact factor: 6.603

Review 9.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

10.  Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology.

Authors:  Qiaojia Huang; Qingling Huang; Wannan Chen; Lin Wang; Wansong Lin; Jianyin Lin; Xu Lin
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-30       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.